Interim FDA Commissioner Kyle Diamantas Working With Pro-Life Leaders on Abortion Pill

When news surfaced that Interim Food and Drug Administration Commissioner Kyle Diamantas would be replacing Marty Makary, who resigned yesterday, pro-life advocates were concerned.

Makary had ignored how the abortion pill has killed millions of babies and injured thousands of women – potentially slow-walking a study meant to limit or prohibit its use.

Also, Diamantas reportedly worked on a case for a Florida branch of the Planned Parenthood abortion business and his name appears as an attorney of record for the abortion company on federal court papers.

However, March for Life President Jennie Bradley Lichter, in a new post on X, says Diamantas is already alleviating those concerns.

Click Like if you are pro-life to like the LifeNews Facebook page!

First, Lichter says Diamantas reached out to pro-life leaders within hours of assuming his new role, signaling an early priority on pro-life issues and the regulation of the abortion pill mifepristone.

Lichter said she had a positive conversation with Diamantas on Tuesday night.

“Had a great convo last night with Kyle Diamantas, the new acting FDA Commissioner,” Lichter wrote. “In other words, within hours of being handed this big new job, he was on the phone with pro-life leaders — which is an encouraging sign of where his priorities lie.”

“After talking w him I’m optimistic that the cause of Life will get a full and fair hearing at the FDA, incl real movement on the mifepristone safety study,” she added.

Lichter said she looks forward to working with the FDA “to make sure abortion drug companies can’t continue to lie to women about their drugs that are NOT ‘safer than Tylenol’ and that abusive men are stopped from ordering these dangerous drugs on the internet and force-feeding them to pregnant women.”

Lichter also commented on reports that, more than a decade ago while a junior associate at a law firm, Diamantas had been listed as counsel for a Planned Parenthood affiliate in a 2017 Florida Supreme Court case.

Lichter addressed those concerns directly.

“It’s true that Diamantas was on a case team representing a Planned Parenthood affiliate in FL when he was a junior associate,” she wrote. “My understanding is that when he was initially put on the case he felt he couldn’t say no — but he ultimately asked to be removed, for conscience reasons. … This was a decade or more ago and has nothing to do with the life-related issues currently before the FDA. In my judgment it is not a reason for concern about his approach in his new job.”

That Lichter, a respected pro-life leader, would feel those concerns are assuaged goes a long way towards trusting that Diamantas could successfully deal with the abortion pill in a way that will save babies and protect women.